Showing results (1521-1530 of 1,542) with videos related to
Sort By:
Pageof 155
Gynecologic Oncology|June 19, 2022
Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancerRachel Campbell, Daniel S J Costa, Martin R Stockler, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomesLucy Haggstrom, Yeh Chen Lee, Clare Scott, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 23, 2021
Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancerPaul A Cohen, Penelope M Webb, Madeleine King, et al.Journal of Gynecologic Oncology|July 1, 2025
Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trialKenichi Harano, Roldano Fossati, Beatriz Pardo, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 24, 2026
Pragmatic gynecologic cancer clinical trials: statements and roadmap from the Gynecologic Cancer InterGroup Chicago Brainstorming MeetingAinhoa Madariaga, Ana Veneziani, Michael Bookman, et al.Journal of Hepatology|September 19, 2025
Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: Long-term efficacy and biomarker explorationYih-Jyh Lin, Da-Liang Ou, Yung-Yeh Su, et al.Clinical and Molecular Hepatology|August 4, 2025
Taiwan Liver Cancer Association Management Consensus Guidelines for Intermediate Stage Hepatocellular CarcinomaI-Cheng Lee, Hung-Wei Wang, Wei Teng, et al.The Lancet. Oncology|April 20, 2023
Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trialLinda R Mileshkin, Kathleen N Moore, Elizabeth H Barnes, et al.The Lancet. Oncology|August 5, 2024
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trialNicoletta Colombo, Elena Biagioli, Kenichi Harano, et al.European Journal of Cancer (Oxford, England : 1990)|March 13, 2020
Age-, sex- and disease subtype-related foetal growth differentials in childhood acute myeloid leukaemia risk: A Childhood Leukemia International Consortium analysisMaria A Karalexi, Nick Dessypris, Xiaomei Ma, et al.Pageof 155